Is Etanercept Safe for Treating Plaque Psoriasis in a Patient With Chronic Hepatitis C Virus Infection?

Gandhi, Rishi K.; Pickup, Tiffany; Sheth, Pranav

doi:10.1001/archdermatol.2010.253

Search citation statements

Order By: Relevance

Paper Sections

Select...

Tnf Blocking Agents (Tnfi)1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2011

2017

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 8 publications

(1 citation statement)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of HCV reactivation was supported by small case studies of patients with psoriasis treated with etanercept (n=3) (category D evidence515). …”

Section: Tnf Blocking Agents (Tnfi)mentioning

confidence: 90%

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1

Fürst

Keystone

So³

et al. 2013

Ann Rheum Dis

120

View full text Add to dashboard Cite

“…The lack of HCV reactivation was supported by small case studies of patients with psoriasis treated with etanercept (n=3) (category D evidence515). …”

Section: Tnf Blocking Agents (Tnfi)mentioning

confidence: 90%

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1

Fürst

Keystone

So³

et al. 2013

Ann Rheum Dis

120

View full text Add to dashboard Cite

Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature

Snast

Atzmony

Braun

et al. 2017

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Etanercept: efficacy and safety for approved indications

Kerensky

Gottlieb

Yaniv

et al. 2011

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Etanercept is a generally well-tolerated treatment for the approved inflammatory diseases. The most common adverse effect of etanercept treatment is injection site reaction, which is generally self-limiting and often does not require treatment. Etanercept may be associated with an increased risk for infection, the development of malignancy, demyelinating disease and congestive heart failure. Fewer patients withdraw from etanercept due to adverse events than with other biologics. For pediatric patients, there are more data for etanercept than other biologics, and etanercept may have lower rates for the development of malignancy.

show abstract

Is Etanercept Safe for Treating Plaque Psoriasis in a Patient With Chronic Hepatitis C Virus Infection?

Abstract: Clinical Question: Is the use of anti-tumor necrosis factor (TNF) therapy, specifically etanercept, effective and safe in the treatment of severe plaque psoriasis in a patient with chronic hepatitis C virus (HCV) infection?

Cited by 8 publications

References 12 publications

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1

Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature

Etanercept: efficacy and safety for approved indications

Contact Info

Product

Resources

About